Background: α1-Adrenoceptor blockers
(α1Bs) are used for the treatment of benign prostatic hyperplasia and
hypertension, but they are known to cause hypotension-related adverse events.
The objective of the present study was to evaluate the
onset time profiles for syncope associated with the use of α1Bs. Methods: We analyzed the data obtained from？the Japanese Adverse Drug Event Report (JADER) databasefor a period from April 2004 until November 2016 and calculated reporting
odds ratios (RORs) for eight α1Bs
available on the Japanese market, using disproportionality analysis. Moreover,
time information recorded in the JADER database was analyzed to evaluate the
onset timesof adverse events. Results: In total, 186,724 reports for males
older than 20 years were analyzed. Significant RORs for syncope,with 95% confidence intervals, were obtained for naftopidil (2.53, 1.81 - 3.53), silodosin (4.24, 2.37 - 5.20), and tamsulosin (2.22, 1.75 - 2.81). The median onset times of syncope for naftopidil, silodosin, and
tamsulosin were 37, 26, and 108 days, respectively. The shape parameters
obtained by fitting the data for the three α1Bsto the Weibull distribution were all less than
1.0, indicating that all thesedrugs could be classified as the early failure type. The cumulative
incidence rates showed that the onset times of syncope tended to be similar
among the three α1Bs.
References
[1]
Japanese Society of Hypertension Guidelines Subcommittee for the Management of Hypertension (2001) Guidelines for the Management of Hypertension for General Practitioners. Hypertension Research, 24, 613-634.
[2]
Japanese Society of Hypertension (2006) Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2004). Hypertension Research, 29, S1-S105.
[3]
Ogihara, T., Kikuchi, K., Matsuoka, H., Fujita, T., Higaki, J., Horiuchi, M., Imai, Y., Imaizumi, T., Ito, S., Iwao, H., Kario, K., Kawano, Y., Kim-Mitsuyama, S., Kimura, G., Matsubara, H., Matsuura, H., Naruse, M., Saito, I., Shimada, K., Shimamoto, K., Suzuki, H., Takishita, S., Tanahashi, N., Tsuchihashi, T., Uchiyama, M., Ueda, S., Ueshima, H., Umemura, S., Ishimitsu, T. and Rakugi, H. (2009) The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertension Research, 32, 3-107. https://doi.org/10.1038/hr.2009.34
[4]
Shimamoto, K., Ando, K., Fujita, T., Hasebe, N., Higaki, J., Horiuchi, M., Imai, Y., Imaizumi, T., Ishimitsu, T., Ito, M., Ito, S., Itoh, H., Iwao, H., Kai, H., Kario, K., Kashihara, N., Kawano, Y., Kim-Mitsuyama, S., Kimura, G., Kohara, K., Komuro, I., Kumagai, H., Matsuura, H., Miura, K., Morishita, R., Naruse, M., Node, K., Ohya, Y., Rakugi, H., Saito, I., Saitoh, S., Shimada, K., Shimosawa, T., Suzuki, H., Tamura, K., Tanahashi, N., Tsuchihashi, T., Uchiyama, M., Ueda, S. and Umemura, S. Japanese Society of Hypertension Committee for Guidelines for the Management of Hypertension (2014) The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertension Research, 37, 253-387. https://doi.org/10.1038/hr.2014.20
[5]
The Japan Geriatrics Society (2015) Guidelines for Medical Treatment and Its Safe for the Elderly 2015. Medical Review, Tokyo.
[6]
The Japanese Urological Association (2011) Clinical Guideline for Benign Prostatic Hyperplasia. RichHill Medical Inc., Tokyo.
[7]
Schwinn, D.A. and Michelotti, G.A. (2000) Alpha11-Adrenergic Receptors in the Lower Urinary Tract and Vascular Bed: Potential Role for the a1D-Subtype in Filling Symptoms and Effects of Ageing on Vascular Expression. BJU International, 85, 6-11. https://doi.org/10.1046/j.1464-410X.2000.00061.x
[8]
Hatano, A., Takahashi, H., Tamaki, M., Komeyama, T., Koizumi, T. and Takeda, M. (1994) Pharmacological Evidence of Distinct Alpha 1-Adrenoreceptor Subtypes Mediating the Contraction of Human Prostatic Urethra and Peripheral Artery. British Journal of Pharmacology, 113, 723-728. https://doi.org/10.1111/j.1476-5381.1994.tb17053.x
[9]
De Mey, C. (1999) Alpha(1)-Blockers for BPH: Are There Differences? European Urology, 36, 52-63. https://doi.org/10.1159/000052349
[10]
Task Force for the Diagnosis and Management of Syncope (2009) Guidelines for the Diagnosis and Management of Syncope (Version 2009). European Heart Journal, 30, 2631-2671.
[11]
Sheldon, R. and Killam, S. (1992) Methodology of Isoproterenol-Tilt Table Testing in Patients with Syncope. Journal of the American College of Cardiology, 19, 773-779. https://doi.org/10.1016/0735-1097(92)90517-Q
[12]
Hori, S. (1994) Diagnosis of Patients with Syncope in Emergency Medicine. Keio Journal of Medicine, 43, 185-191.
[13]
Bänsch, D., Brunn, J., Castrucci, M., Weber, M., Gietzen, F., Borggrefe, M., Breithardt, G. and Block, M. (1998) Syncope in Patients with an Implantable Cardioverter-Defibrillator: Incidence, Prediction and Implications for Driving Restrictions. Journal of the American College of Cardiology, 31, 608-615. https://doi.org/10.1016/S0735-1097(97)00543-3
[14]
Bhatia, A., Dhala, A., Blanck, Z., Deshpande, S., Akhtar, M. and Sra, A.J. (1999) Driving Safety among Patients with Neurocardiogenic (Vasovagal) Syncope. Pacing and Clinical Electrophysiology, 22, 1576-1580. https://doi.org/10.1111/j.1540-8159.1999.tb00375.x
[15]
Nakamura, M., Umetsu, R., Abe, J., Matsui, T., Ueda, N., Kato, Y., Sasaoka, S., Tahara, K., Takeuchi, H. and Kinosada, Y. (2015) Analysis of the Time-to-Onset of Osteonecrosis of Jaw with Bisphosphonate Treatment Using the Data from a Spontaneous Reporting System of Adverse Drug Events. Journal of Pharmaceutical Health Care and Science, 1, 34. https://doi.org/10.1186/s40780-015-0035-2
[16]
Kose, E., Uno, K. and Hayashi, H. (2017) Evaluation of the Expression Profile of Extrapyramidal Symptoms Due to Antipsychotics by Data Mining of Japanese Adverse Drug Event Report (JADER) Database. Yakugaku Zasshi, 137, 111-120. https://doi.org/10.1248/yakushi.16-00219
[17]
Hara, A., Matsumoto, K., Yokoyama, Y. and Kizu, J. (2017) Factorial Analysis of Hepatitis B Virus Reactivation-Induced Hepatitis B Using JADER. Biological and Pharmaceutical Bulletin, 40, 782-788. https://doi.org/10.1248/bpb.b16-00765
[18]
Noguchi, Y., Katsuno, H., Ueno, A., Otsubo, M., Yoshida, A., Kanematsu, Y., Sugita, I., Esaki, H., Tachi, T., Tsuchiya, T. and Teramachi, H. (2018) Signals of Gastroesophageal Reflux Disease Caused by Incretin-Based Drugs: A Disproportionality Analysis Using the Japanese Adverse Drug Event Report Database. Journal of Pharmaceutical Health Care and Science, 4, 15. https://doi.org/10.1186/s40780-018-0109-z
[19]
Van Puijenbroek, E.P., Bate, A., Leufkens, H.G., Lindquist, M., Orre, R. and Egberts, A.C. (2002) A Comparison of Measures of Disproportionality for Signal Detection in Spontaneous Reporting Systems for Adverse Drug Reactions. Pharmacoepidemiology and Drug Safety, 11, 3-10. https://doi.org/10.1002/pds.668
[20]
Fujita, T. (2009) Signal Detection of Adverse Drug Reactions. Japanese Journal of Pharmacoepidemiology, 14, 27-36.
[21]
Suzuki, Y., Suzuki, H., Umetsu, R., Uranishi, H., Abe, J., Nishibata, Y., Sekiya, Y., Miyamura, N., Hara, H., Tsuchiya, T., Kinosada, Y. and Nakamura, M. (2015) Analysis of the Interaction between Clopidogrel, Aspirin, and Proton Pump Inhibitors Using the FDA Adverse Event Reporting System Database. Biological and Pharmaceutical Bulletin, 38, 680-686. https://doi.org/10.1248/bpb.b14-00191
[22]
Fujimoto, M., Kanou, M., Hosomi, K. and Takada, M. (2017) Angiotensin Receptor Blockers and the Risk of Cancer: Data Mining of a Spontaneous Reporting Database and a Claims Database. International Journal of Clinical Pharmacology and Therapeutics, 55, 295-303. https://doi.org/10.5414/CP202842
[23]
Sauzet, O., Carvajal, A., Escudero, A., Molokhia, M. and Cornelius, V.R. (2013) Illustration of the Weibull Shape Parameter Signal Detection Tool Using Electronic Healthcare Record Data. Drug Safety, 36, 995-1006. https://doi.org/10.1007/s40264-013-0061-7
[24]
Yamada, M. and Handa, J. (2014) Comparison of the Onset Time Profile among the Interferon Formulations in Adverse Drug Reaction of Suicide- or Diabetes-Related. Japanese Journal of Pharmacoepidemiology, 19, 23-30. https://doi.org/10.3820/jjpe.19.23
[25]
Takei, R., Ikegaki, I., Shibata, K., Tsujimoto, G. and Asano, T. (1999) Naftopidil, a Novel α1-Adrenoceptor Antagonist, Displays Selective Inhibition of Canine Prostatic Pressure and High Affinity Binding to Cloned Human α1-Adrenoceptors. Japanese Journal of Pharmacology, 79, 447-454. https://doi.org/10.1254/jjp.79.447
[26]
Shibata, K., Foglar, R., Horie, K., Obika, K., Sakamoto, A., Ogawa, S. and Tsujimoto, G. (1995) KMD-3213, a Novel, Potent, α1a-Adrenoceptor-Selective Antagonist: Characterization Using Recombinant Human α1-Adrenoceptors and Native Tissues. Molecular Pharmacology, 48, 250-258.
[27]
Lai, C.L., Kuo, R.N., Chen, H.M., Chen, M.F., Chan, K.A. and Lai, M.S. (2016) Risk of Ischemic Stroke during the Initiation Period of α-Blocker Therapy among Older Men. Canadian Medical Association Journal, 188, 255-260. https://doi.org/10.1503/cmaj.150624
[28]
Lai, C.L., Kuo, R.N., Chen, H.M., Chen, M.F., Chan, K.A. and Lai, M.S. (2015) Risk of Hip/Femur Fractures during the Initiation Period of α-Adrenoceptor Blocker Therapy among Elderly Males: A Self-Controlled Case Series Study. British Journal of Clinical Pharmacology, 80, 1208-1218. https://doi.org/10.1111/bcp.12671
[29]
Poluzzi, E., Raschi, E., Moretti, U. and De Ponti, F. (2009) Drug-Induced Torsades de Pointes: Data Mining of the Public Version of the FDA Adverse Event Reporting System (AERS). Pharmacoepidemiology and Drug Safety, 18, 512-518. https://doi.org/10.1002/pds.1746
